TPMT and myelosuppression: There were only two (1.8%) patients with heterozygous mutations of TPMT*3C, and neither of them exhibited myelosuppression; however, among TPMT*3C wild-type allele carriers, 15 (13.5%) patients suffered leukopenia, 34 (30.6%) suffered thrombocytopenia, and 10 (9.0%) experienced neutropenia.